Clinical and Immunological Evaluation of Application of Ronkoleukin in Nonspecific Vulvovaginitis at Adolescent Girls

Abstract

Package Insert: According to immunological parameters there was found that during the sub-acute there is the secondary immune deficiency and the immunodeficiency is absent during the acute. During the acute phagocytic function of the local secret is satisfactory, and during the sub-acute against satisfactory absorption function there is a decrease of bacterial growth-inhibitory activity of vaginal secretions, indicating the necessity of correction of phagocytic component of these patients. The Purpose of the Research: Clinical and immunological evaluation of ronkoleukin using depending on the routes of entry in the treatment of non-specific vulvovaginitis among adolescent girls in different variants of the disease state. Design of their Search: Prospective study. Methodology: From 2006 to 2010 years by the assignment of adolescent therapist and upon periodic screening the adolescent girls with a variety of complains for genitalia were examined in the child and adolescent consulting room in Municipal Polyclinic No 11 and «The City Center of Human Original Research Article Kenzhebekovna and Medeubaevna; BJMMR, 10(8): 1-12, 2015; Article no.BJMMR.18891 2 Reproduction» in Almaty. 124 menstruate adolescent girls from 11 to 18 years, not sexually active, were selected to accomplish the target objective. I group -20 healthy (control). II group 62 with per-acute nonspecific vulvovaginitis. III group 42 with sub-acute nonspecific vulvovaginitis. In cooperation with the scientific consultant and immunologist, M.D. Prof. A. Kurmanova there was developed a dosage schedule of roncoleukine in the complex therapy, based on the results of the analyses of the immune and cytokine status and phagocytic vaginal system. II group 62 patients with per-acute nonspecific vulvovaginitis. II А– 20 patients with sub-acute nonspecific vulvovaginitis. (Standard therapy + roncoleukine 250 000 U/ml vaginal irrigation once a day). II B– 25 adolescent girls with sub-acute. (Standard therapy + roncoleukine 250 000 U/ml twice subcutaneously, every other day). II C – 17 adolescent girls with sub-acute (standard therapy). III group 42 patients with acute nonspecific vulvovaginitis. (standard therapy + roncoleukine 250 000 U/ml twice subcutaneously, every other day). Standard therapy of 7-10 days included [1,2]: Efficacy of the drug was assessed by patient complaints, inspection, and data of microbiological studies of vaginal discharge, immune state, cytokine status, and local phagocytic system on the 7th and 14th days of treatment.